AZA issue
"A SWOT analysis is a strategic planning tool used to identify the Strengths, Weaknesses, Opportunities, and Threats of a project, business, or personal goal "
https://www.ibisworld.com/blog/how-to-do-a-swot-analysis/1/1127/
How do partners, competitors or possible buyers evaluate Faron? WE can evaluate them... Threats are the strongest driving forces in their minds.
Toolkit:
As a driving force 1 are strengths of Faron
As a driving force 2 are the threats of Big Pharma itself...
Let us make an example, of current interest - AZA:
https://mdspatientsupport.org.uk/what-is-mds/azacitidine-vidaza/
"Hypomethylating agents are less intensive than other types of chemotherapy. The aim of hypomethylating agents is to slow the progression of the disease while at the same time producing as few side effects as possible, thereby having a gentler impact on quality of life. Although Azacitidine cannot cure MDS, and doesn’t work for everyone, it may ‘modify’ it and even reduce the frequency of blood transfusions. In some cases (mostly when treating high-risk patients) other drugs can be used in conjunction with Aza to make it more effective. Research into these drug combinations is ongoing, and the results are generally encouraging... Azacitidine works at the DNA level, by "switching on" particular genes that can stop cancer cells growing and dividing. This reduces the number of abnormal blood cells and helps to control cell growth."
AZA was approved by FDA in 2004 and it is still under development:
https://www.databridgemarketresearch.com/reports/global-azacitidine-market
The Major Market Leaders Operating in the Market Are:
- Novartis AG (Switzerland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Abbott (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bausch Health Companies Inc. (Canada)
- AstraZeneca (U.K.)
- GSK plc (U.K.)
- H. Lundbeck A/S (Denmark)
- Takeda Pharmaceutical Company Limited (Japan)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Eisai Co., Ltd (Japan)
- Merz Pharma (Germany)
A promise of competition! BEX + AZA?
(Especially mentioned:) "Leading pharmaceutical companies such as Bristol Myers Squibb, Pfizer, and Takeda Pharmaceutical are investing heavily in new drug formulations, clinical trials, and combination therapies to expand the therapeutic applications of azacitidine."
Suddenly I understood that BEXMAB was a neutral investigation without a supplier of AZA!
>> Faron's first pact?
Kommentit
Lähetä kommentti